Service & Software
Global Human Vaccine Contract Manufacturing Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 583105
- Pages: 151
- Figures: 155
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Human Vaccine Contract Manufacturing market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Ajinomoto Althea, Inc.
Merck KgaA
Cytovance Biologics
Catalent, Inc.
IDT Biologika GmbH
Albany Molecular Research, Inc.
PRA Health Sciences
ICON plc.
Pharmaceutical Product Development, LLC
Cobra Bio
Paragon Bioservices, Inc.
Emergent BioSolutions Inc.
CSL Limited
BioNTech SE
Wuxi Biologics
Samsung Biologics
Boehringer Ingelheim
Novavax, Inc.
Segment by Type
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based
Segment by Application
Downstream
Upstream
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Human Vaccine Contract Manufacturing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Human Vaccine Contract Manufacturing market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Ajinomoto Althea, Inc.
Merck KgaA
Cytovance Biologics
Catalent, Inc.
IDT Biologika GmbH
Albany Molecular Research, Inc.
PRA Health Sciences
ICON plc.
Pharmaceutical Product Development, LLC
Cobra Bio
Paragon Bioservices, Inc.
Emergent BioSolutions Inc.
CSL Limited
BioNTech SE
Wuxi Biologics
Samsung Biologics
Boehringer Ingelheim
Novavax, Inc.
Segment by Type
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based
Segment by Application
Downstream
Upstream
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Human Vaccine Contract Manufacturing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Human Vaccine Contract Manufacturing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Human Vaccine Contract Manufacturing Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Attenuated
1.2.3 Inactivated
1.2.4 Subunit-based
1.2.5 Toxoid-based
1.2.6 DNA-based
1.3 Market Segmentation by Application
1.3.1 Global Human Vaccine Contract Manufacturing Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Downstream
1.3.3 Upstream
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Vaccine Contract Manufacturing Revenue Estimates and Forecasts 2020-2031
2.2 Global Human Vaccine Contract Manufacturing Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Human Vaccine Contract Manufacturing Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Human Vaccine Contract Manufacturing Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Attenuated Market Size by Players
3.3.2 Inactivated Market Size by Players
3.3.3 Subunit-based Market Size by Players
3.3.4 Toxoid-based Market Size by Players
3.3.5 DNA-based Market Size by Players
3.4 Global Human Vaccine Contract Manufacturing Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Human Vaccine Contract Manufacturing Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Human Vaccine Contract Manufacturing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
6.4 North America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Human Vaccine Contract Manufacturing Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
7.4 Europe Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Human Vaccine Contract Manufacturing Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
8.4 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
9.4 Central and South America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Human Vaccine Contract Manufacturing Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
10.4 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Human Vaccine Contract Manufacturing Product Features and Attributes
11.1.4 Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.1.5 Lonza Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.1.6 Lonza Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.1.7 Lonza Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.1.8 Lonza Human Vaccine Contract Manufacturing SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
11.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Corporation Information
11.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
11.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.2.6 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.2.7 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.2.8 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing SWOT Analysis
11.2.9 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
11.3 Ajinomoto Althea, Inc.
11.3.1 Ajinomoto Althea, Inc. Corporation Information
11.3.2 Ajinomoto Althea, Inc. Business Overview
11.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.3.5 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.3.6 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.3.7 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.3.8 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing SWOT Analysis
11.3.9 Ajinomoto Althea, Inc. Recent Developments
11.4 Merck KgaA
11.4.1 Merck KgaA Corporation Information
11.4.2 Merck KgaA Business Overview
11.4.3 Merck KgaA Human Vaccine Contract Manufacturing Product Features and Attributes
11.4.4 Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.4.5 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.4.6 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.4.7 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.4.8 Merck KgaA Human Vaccine Contract Manufacturing SWOT Analysis
11.4.9 Merck KgaA Recent Developments
11.5 Cytovance Biologics
11.5.1 Cytovance Biologics Corporation Information
11.5.2 Cytovance Biologics Business Overview
11.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.5.5 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.5.6 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.5.7 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.5.8 Cytovance Biologics Human Vaccine Contract Manufacturing SWOT Analysis
11.5.9 Cytovance Biologics Recent Developments
11.6 Catalent, Inc.
11.6.1 Catalent, Inc. Corporation Information
11.6.2 Catalent, Inc. Business Overview
11.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.6.5 Catalent, Inc. Recent Developments
11.7 IDT Biologika GmbH
11.7.1 IDT Biologika GmbH Corporation Information
11.7.2 IDT Biologika GmbH Business Overview
11.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Features and Attributes
11.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.7.5 IDT Biologika GmbH Recent Developments
11.8 Albany Molecular Research, Inc.
11.8.1 Albany Molecular Research, Inc. Corporation Information
11.8.2 Albany Molecular Research, Inc. Business Overview
11.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.8.5 Albany Molecular Research, Inc. Recent Developments
11.9 PRA Health Sciences
11.9.1 PRA Health Sciences Corporation Information
11.9.2 PRA Health Sciences Business Overview
11.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Product Features and Attributes
11.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.9.5 PRA Health Sciences Recent Developments
11.10 ICON plc.
11.10.1 ICON plc. Corporation Information
11.10.2 ICON plc. Business Overview
11.10.3 ICON plc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.10.4 ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Pharmaceutical Product Development, LLC
11.11.1 Pharmaceutical Product Development, LLC Corporation Information
11.11.2 Pharmaceutical Product Development, LLC Business Overview
11.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Features and Attributes
11.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.11.5 Pharmaceutical Product Development, LLC Recent Developments
11.12 Cobra Bio
11.12.1 Cobra Bio Corporation Information
11.12.2 Cobra Bio Business Overview
11.12.3 Cobra Bio Human Vaccine Contract Manufacturing Product Features and Attributes
11.12.4 Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.12.5 Cobra Bio Recent Developments
11.13 Paragon Bioservices, Inc.
11.13.1 Paragon Bioservices, Inc. Corporation Information
11.13.2 Paragon Bioservices, Inc. Business Overview
11.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.13.5 Paragon Bioservices, Inc. Recent Developments
11.14 Emergent BioSolutions Inc.
11.14.1 Emergent BioSolutions Inc. Corporation Information
11.14.2 Emergent BioSolutions Inc. Business Overview
11.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.14.5 Emergent BioSolutions Inc. Recent Developments
11.15 CSL Limited
11.15.1 CSL Limited Corporation Information
11.15.2 CSL Limited Business Overview
11.15.3 CSL Limited Human Vaccine Contract Manufacturing Product Features and Attributes
11.15.4 CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.15.5 CSL Limited Recent Developments
11.16 BioNTech SE
11.16.1 BioNTech SE Corporation Information
11.16.2 BioNTech SE Business Overview
11.16.3 BioNTech SE Human Vaccine Contract Manufacturing Product Features and Attributes
11.16.4 BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.16.5 BioNTech SE Recent Developments
11.17 Wuxi Biologics
11.17.1 Wuxi Biologics Corporation Information
11.17.2 Wuxi Biologics Business Overview
11.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.17.5 Wuxi Biologics Recent Developments
11.18 Samsung Biologics
11.18.1 Samsung Biologics Corporation Information
11.18.2 Samsung Biologics Business Overview
11.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.18.5 Samsung Biologics Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Corporation Information
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Features and Attributes
11.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.19.5 Boehringer Ingelheim Recent Developments
11.20 Novavax, Inc.
11.20.1 Novavax, Inc. Corporation Information
11.20.2 Novavax, Inc. Business Overview
11.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.20.5 Novavax, Inc. Recent Developments
12 Human Vaccine Contract ManufacturingIndustry Chain Analysis
12.1 Human Vaccine Contract Manufacturing Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Human Vaccine Contract Manufacturing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Human Vaccine Contract Manufacturing Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Human Vaccine Contract Manufacturing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Human Vaccine Contract Manufacturing Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Attenuated
1.2.3 Inactivated
1.2.4 Subunit-based
1.2.5 Toxoid-based
1.2.6 DNA-based
1.3 Market Segmentation by Application
1.3.1 Global Human Vaccine Contract Manufacturing Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Downstream
1.3.3 Upstream
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Vaccine Contract Manufacturing Revenue Estimates and Forecasts 2020-2031
2.2 Global Human Vaccine Contract Manufacturing Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Human Vaccine Contract Manufacturing Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Human Vaccine Contract Manufacturing Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Attenuated Market Size by Players
3.3.2 Inactivated Market Size by Players
3.3.3 Subunit-based Market Size by Players
3.3.4 Toxoid-based Market Size by Players
3.3.5 DNA-based Market Size by Players
3.4 Global Human Vaccine Contract Manufacturing Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Human Vaccine Contract Manufacturing Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Human Vaccine Contract Manufacturing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
6.4 North America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Human Vaccine Contract Manufacturing Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
7.4 Europe Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Human Vaccine Contract Manufacturing Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
8.4 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
9.4 Central and South America Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Human Vaccine Contract Manufacturing Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Type (2020-2031)
10.4 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Human Vaccine Contract Manufacturing Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Human Vaccine Contract Manufacturing Product Features and Attributes
11.1.4 Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.1.5 Lonza Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.1.6 Lonza Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.1.7 Lonza Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.1.8 Lonza Human Vaccine Contract Manufacturing SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
11.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Corporation Information
11.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
11.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.2.6 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.2.7 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.2.8 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing SWOT Analysis
11.2.9 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
11.3 Ajinomoto Althea, Inc.
11.3.1 Ajinomoto Althea, Inc. Corporation Information
11.3.2 Ajinomoto Althea, Inc. Business Overview
11.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.3.5 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.3.6 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.3.7 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.3.8 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing SWOT Analysis
11.3.9 Ajinomoto Althea, Inc. Recent Developments
11.4 Merck KgaA
11.4.1 Merck KgaA Corporation Information
11.4.2 Merck KgaA Business Overview
11.4.3 Merck KgaA Human Vaccine Contract Manufacturing Product Features and Attributes
11.4.4 Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.4.5 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.4.6 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.4.7 Merck KgaA Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.4.8 Merck KgaA Human Vaccine Contract Manufacturing SWOT Analysis
11.4.9 Merck KgaA Recent Developments
11.5 Cytovance Biologics
11.5.1 Cytovance Biologics Corporation Information
11.5.2 Cytovance Biologics Business Overview
11.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.5.5 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Product in 2024
11.5.6 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Application in 2024
11.5.7 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue by Geographic Area in 2024
11.5.8 Cytovance Biologics Human Vaccine Contract Manufacturing SWOT Analysis
11.5.9 Cytovance Biologics Recent Developments
11.6 Catalent, Inc.
11.6.1 Catalent, Inc. Corporation Information
11.6.2 Catalent, Inc. Business Overview
11.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.6.5 Catalent, Inc. Recent Developments
11.7 IDT Biologika GmbH
11.7.1 IDT Biologika GmbH Corporation Information
11.7.2 IDT Biologika GmbH Business Overview
11.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Features and Attributes
11.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.7.5 IDT Biologika GmbH Recent Developments
11.8 Albany Molecular Research, Inc.
11.8.1 Albany Molecular Research, Inc. Corporation Information
11.8.2 Albany Molecular Research, Inc. Business Overview
11.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.8.5 Albany Molecular Research, Inc. Recent Developments
11.9 PRA Health Sciences
11.9.1 PRA Health Sciences Corporation Information
11.9.2 PRA Health Sciences Business Overview
11.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Product Features and Attributes
11.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.9.5 PRA Health Sciences Recent Developments
11.10 ICON plc.
11.10.1 ICON plc. Corporation Information
11.10.2 ICON plc. Business Overview
11.10.3 ICON plc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.10.4 ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Pharmaceutical Product Development, LLC
11.11.1 Pharmaceutical Product Development, LLC Corporation Information
11.11.2 Pharmaceutical Product Development, LLC Business Overview
11.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Features and Attributes
11.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.11.5 Pharmaceutical Product Development, LLC Recent Developments
11.12 Cobra Bio
11.12.1 Cobra Bio Corporation Information
11.12.2 Cobra Bio Business Overview
11.12.3 Cobra Bio Human Vaccine Contract Manufacturing Product Features and Attributes
11.12.4 Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.12.5 Cobra Bio Recent Developments
11.13 Paragon Bioservices, Inc.
11.13.1 Paragon Bioservices, Inc. Corporation Information
11.13.2 Paragon Bioservices, Inc. Business Overview
11.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.13.5 Paragon Bioservices, Inc. Recent Developments
11.14 Emergent BioSolutions Inc.
11.14.1 Emergent BioSolutions Inc. Corporation Information
11.14.2 Emergent BioSolutions Inc. Business Overview
11.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.14.5 Emergent BioSolutions Inc. Recent Developments
11.15 CSL Limited
11.15.1 CSL Limited Corporation Information
11.15.2 CSL Limited Business Overview
11.15.3 CSL Limited Human Vaccine Contract Manufacturing Product Features and Attributes
11.15.4 CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.15.5 CSL Limited Recent Developments
11.16 BioNTech SE
11.16.1 BioNTech SE Corporation Information
11.16.2 BioNTech SE Business Overview
11.16.3 BioNTech SE Human Vaccine Contract Manufacturing Product Features and Attributes
11.16.4 BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.16.5 BioNTech SE Recent Developments
11.17 Wuxi Biologics
11.17.1 Wuxi Biologics Corporation Information
11.17.2 Wuxi Biologics Business Overview
11.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.17.5 Wuxi Biologics Recent Developments
11.18 Samsung Biologics
11.18.1 Samsung Biologics Corporation Information
11.18.2 Samsung Biologics Business Overview
11.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Product Features and Attributes
11.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.18.5 Samsung Biologics Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Corporation Information
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Features and Attributes
11.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.19.5 Boehringer Ingelheim Recent Developments
11.20 Novavax, Inc.
11.20.1 Novavax, Inc. Corporation Information
11.20.2 Novavax, Inc. Business Overview
11.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Product Features and Attributes
11.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2020-2025)
11.20.5 Novavax, Inc. Recent Developments
12 Human Vaccine Contract ManufacturingIndustry Chain Analysis
12.1 Human Vaccine Contract Manufacturing Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Human Vaccine Contract Manufacturing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Human Vaccine Contract Manufacturing Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Human Vaccine Contract Manufacturing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Vaccine Contract Manufacturing Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Human Vaccine Contract Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Human Vaccine Contract Manufacturing by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccine Contract Manufacturing as of 2024)
Table 11. Global Human Vaccine Contract Manufacturing Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Human Vaccine Contract Manufacturing Companies Headquarters
Table 13. Global Human Vaccine Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Human Vaccine Contract Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Human Vaccine Contract Manufacturing Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Human Vaccine Contract Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Human Vaccine Contract Manufacturing Revenue by Application (2026-2031) & (US$ Million)
Table 21. Human Vaccine Contract Manufacturing High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 25. North America Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 27. Europe Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Human Vaccine Contract Manufacturing Investment Opportunities and Key Challenges
Table 31. Central and South America Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Human Vaccine Contract Manufacturing Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Lonza Corporation Information
Table 35. Lonza Description and Major Businesses
Table 36. Lonza Product Features and Attributes
Table 37. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Lonza Revenue Proportion by Product in 2024
Table 39. Lonza Revenue Proportion by Application in 2024
Table 40. Lonza Revenue Proportion by Geographic Area in 2024
Table 41. Lonza Human Vaccine Contract Manufacturing SWOT Analysis
Table 42. Lonza Recent Developments
Table 43. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Corporation Information
Table 44. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Description and Major Businesses
Table 45. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Product Features and Attributes
Table 46. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Product in 2024
Table 48. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Application in 2024
Table 49. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Geographic Area in 2024
Table 50. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing SWOT Analysis
Table 51. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
Table 52. Ajinomoto Althea, Inc. Corporation Information
Table 53. Ajinomoto Althea, Inc. Description and Major Businesses
Table 54. Ajinomoto Althea, Inc. Product Features and Attributes
Table 55. Ajinomoto Althea, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Ajinomoto Althea, Inc. Revenue Proportion by Product in 2024
Table 57. Ajinomoto Althea, Inc. Revenue Proportion by Application in 2024
Table 58. Ajinomoto Althea, Inc. Revenue Proportion by Geographic Area in 2024
Table 59. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing SWOT Analysis
Table 60. Ajinomoto Althea, Inc. Recent Developments
Table 61. Merck KgaA Corporation Information
Table 62. Merck KgaA Description and Major Businesses
Table 63. Merck KgaA Product Features and Attributes
Table 64. Merck KgaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Merck KgaA Revenue Proportion by Product in 2024
Table 66. Merck KgaA Revenue Proportion by Application in 2024
Table 67. Merck KgaA Revenue Proportion by Geographic Area in 2024
Table 68. Merck KgaA Human Vaccine Contract Manufacturing SWOT Analysis
Table 69. Merck KgaA Recent Developments
Table 70. Cytovance Biologics Corporation Information
Table 71. Cytovance Biologics Description and Major Businesses
Table 72. Cytovance Biologics Product Features and Attributes
Table 73. Cytovance Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Cytovance Biologics Revenue Proportion by Product in 2024
Table 75. Cytovance Biologics Revenue Proportion by Application in 2024
Table 76. Cytovance Biologics Revenue Proportion by Geographic Area in 2024
Table 77. Cytovance Biologics Human Vaccine Contract Manufacturing SWOT Analysis
Table 78. Cytovance Biologics Recent Developments
Table 79. Catalent, Inc. Corporation Information
Table 80. Catalent, Inc. Description and Major Businesses
Table 81. Catalent, Inc. Product Features and Attributes
Table 82. Catalent, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Catalent, Inc. Recent Developments
Table 84. IDT Biologika GmbH Corporation Information
Table 85. IDT Biologika GmbH Description and Major Businesses
Table 86. IDT Biologika GmbH Product Features and Attributes
Table 87. IDT Biologika GmbH Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. IDT Biologika GmbH Recent Developments
Table 89. Albany Molecular Research, Inc. Corporation Information
Table 90. Albany Molecular Research, Inc. Description and Major Businesses
Table 91. Albany Molecular Research, Inc. Product Features and Attributes
Table 92. Albany Molecular Research, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Albany Molecular Research, Inc. Recent Developments
Table 94. PRA Health Sciences Corporation Information
Table 95. PRA Health Sciences Description and Major Businesses
Table 96. PRA Health Sciences Product Features and Attributes
Table 97. PRA Health Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. PRA Health Sciences Recent Developments
Table 99. ICON plc. Corporation Information
Table 100. ICON plc. Description and Major Businesses
Table 101. ICON plc. Product Features and Attributes
Table 102. ICON plc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. ICON plc. Recent Developments
Table 104. Pharmaceutical Product Development, LLC Corporation Information
Table 105. Pharmaceutical Product Development, LLC Description and Major Businesses
Table 106. Pharmaceutical Product Development, LLC Product Features and Attributes
Table 107. Pharmaceutical Product Development, LLC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Pharmaceutical Product Development, LLC Recent Developments
Table 109. Cobra Bio Corporation Information
Table 110. Cobra Bio Description and Major Businesses
Table 111. Cobra Bio Product Features and Attributes
Table 112. Cobra Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Cobra Bio Recent Developments
Table 114. Paragon Bioservices, Inc. Corporation Information
Table 115. Paragon Bioservices, Inc. Description and Major Businesses
Table 116. Paragon Bioservices, Inc. Product Features and Attributes
Table 117. Paragon Bioservices, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Paragon Bioservices, Inc. Recent Developments
Table 119. Emergent BioSolutions Inc. Corporation Information
Table 120. Emergent BioSolutions Inc. Description and Major Businesses
Table 121. Emergent BioSolutions Inc. Product Features and Attributes
Table 122. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Emergent BioSolutions Inc. Recent Developments
Table 124. CSL Limited Corporation Information
Table 125. CSL Limited Description and Major Businesses
Table 126. CSL Limited Product Features and Attributes
Table 127. CSL Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. CSL Limited Recent Developments
Table 129. BioNTech SE Corporation Information
Table 130. BioNTech SE Description and Major Businesses
Table 131. BioNTech SE Product Features and Attributes
Table 132. BioNTech SE Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. BioNTech SE Recent Developments
Table 134. Wuxi Biologics Corporation Information
Table 135. Wuxi Biologics Description and Major Businesses
Table 136. Wuxi Biologics Product Features and Attributes
Table 137. Wuxi Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Wuxi Biologics Recent Developments
Table 139. Samsung Biologics Corporation Information
Table 140. Samsung Biologics Description and Major Businesses
Table 141. Samsung Biologics Product Features and Attributes
Table 142. Samsung Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Samsung Biologics Recent Developments
Table 144. Boehringer Ingelheim Corporation Information
Table 145. Boehringer Ingelheim Description and Major Businesses
Table 146. Boehringer Ingelheim Product Features and Attributes
Table 147. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Boehringer Ingelheim Recent Developments
Table 149. Novavax, Inc. Corporation Information
Table 150. Novavax, Inc. Description and Major Businesses
Table 151. Novavax, Inc. Product Features and Attributes
Table 152. Novavax, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Novavax, Inc. Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Vaccine Contract Manufacturing Product Picture
Figure 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Attenuated Product Picture
Figure 4. Inactivated Product Picture
Figure 5. Subunit-based Product Picture
Figure 6. Toxoid-based Product Picture
Figure 7. DNA-based Product Picture
Figure 8. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Downstream
Figure 10. Upstream
Figure 11. Human Vaccine Contract Manufacturing Report Years Considered
Figure 12. Global Human Vaccine Contract Manufacturing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 14. Global Human Vaccine Contract Manufacturing Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Human Vaccine Contract Manufacturing Revenue Market Share by Region (2020-2031)
Figure 16. Global Human Vaccine Contract Manufacturing Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Attenuated Revenue Market Share by Player in 2024
Figure 19. Inactivated Revenue Market Share by Player in 2024
Figure 20. Subunit-based Revenue Market Share by Player in 2024
Figure 21. Toxoid-based Revenue Market Share by Player in 2024
Figure 22. DNA-based Revenue Market Share by Player in 2024
Figure 23. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2020-2031)
Figure 24. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2020-2031)
Figure 25. North America Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 27. North America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 34. Europe Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 37. France Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 49. India Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 57. Central and South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 63. South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 69. Human Vaccine Contract Manufacturing Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Table 1. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Human Vaccine Contract Manufacturing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Vaccine Contract Manufacturing Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Human Vaccine Contract Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Human Vaccine Contract Manufacturing by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccine Contract Manufacturing as of 2024)
Table 11. Global Human Vaccine Contract Manufacturing Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Human Vaccine Contract Manufacturing Companies Headquarters
Table 13. Global Human Vaccine Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Human Vaccine Contract Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Human Vaccine Contract Manufacturing Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Human Vaccine Contract Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Human Vaccine Contract Manufacturing Revenue by Application (2026-2031) & (US$ Million)
Table 21. Human Vaccine Contract Manufacturing High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 25. North America Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 27. Europe Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Human Vaccine Contract Manufacturing Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Human Vaccine Contract Manufacturing Investment Opportunities and Key Challenges
Table 31. Central and South America Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Human Vaccine Contract Manufacturing Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Human Vaccine Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Lonza Corporation Information
Table 35. Lonza Description and Major Businesses
Table 36. Lonza Product Features and Attributes
Table 37. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Lonza Revenue Proportion by Product in 2024
Table 39. Lonza Revenue Proportion by Application in 2024
Table 40. Lonza Revenue Proportion by Geographic Area in 2024
Table 41. Lonza Human Vaccine Contract Manufacturing SWOT Analysis
Table 42. Lonza Recent Developments
Table 43. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Corporation Information
Table 44. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Description and Major Businesses
Table 45. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Product Features and Attributes
Table 46. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Product in 2024
Table 48. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Application in 2024
Table 49. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Proportion by Geographic Area in 2024
Table 50. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing SWOT Analysis
Table 51. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
Table 52. Ajinomoto Althea, Inc. Corporation Information
Table 53. Ajinomoto Althea, Inc. Description and Major Businesses
Table 54. Ajinomoto Althea, Inc. Product Features and Attributes
Table 55. Ajinomoto Althea, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Ajinomoto Althea, Inc. Revenue Proportion by Product in 2024
Table 57. Ajinomoto Althea, Inc. Revenue Proportion by Application in 2024
Table 58. Ajinomoto Althea, Inc. Revenue Proportion by Geographic Area in 2024
Table 59. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing SWOT Analysis
Table 60. Ajinomoto Althea, Inc. Recent Developments
Table 61. Merck KgaA Corporation Information
Table 62. Merck KgaA Description and Major Businesses
Table 63. Merck KgaA Product Features and Attributes
Table 64. Merck KgaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Merck KgaA Revenue Proportion by Product in 2024
Table 66. Merck KgaA Revenue Proportion by Application in 2024
Table 67. Merck KgaA Revenue Proportion by Geographic Area in 2024
Table 68. Merck KgaA Human Vaccine Contract Manufacturing SWOT Analysis
Table 69. Merck KgaA Recent Developments
Table 70. Cytovance Biologics Corporation Information
Table 71. Cytovance Biologics Description and Major Businesses
Table 72. Cytovance Biologics Product Features and Attributes
Table 73. Cytovance Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Cytovance Biologics Revenue Proportion by Product in 2024
Table 75. Cytovance Biologics Revenue Proportion by Application in 2024
Table 76. Cytovance Biologics Revenue Proportion by Geographic Area in 2024
Table 77. Cytovance Biologics Human Vaccine Contract Manufacturing SWOT Analysis
Table 78. Cytovance Biologics Recent Developments
Table 79. Catalent, Inc. Corporation Information
Table 80. Catalent, Inc. Description and Major Businesses
Table 81. Catalent, Inc. Product Features and Attributes
Table 82. Catalent, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Catalent, Inc. Recent Developments
Table 84. IDT Biologika GmbH Corporation Information
Table 85. IDT Biologika GmbH Description and Major Businesses
Table 86. IDT Biologika GmbH Product Features and Attributes
Table 87. IDT Biologika GmbH Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. IDT Biologika GmbH Recent Developments
Table 89. Albany Molecular Research, Inc. Corporation Information
Table 90. Albany Molecular Research, Inc. Description and Major Businesses
Table 91. Albany Molecular Research, Inc. Product Features and Attributes
Table 92. Albany Molecular Research, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Albany Molecular Research, Inc. Recent Developments
Table 94. PRA Health Sciences Corporation Information
Table 95. PRA Health Sciences Description and Major Businesses
Table 96. PRA Health Sciences Product Features and Attributes
Table 97. PRA Health Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. PRA Health Sciences Recent Developments
Table 99. ICON plc. Corporation Information
Table 100. ICON plc. Description and Major Businesses
Table 101. ICON plc. Product Features and Attributes
Table 102. ICON plc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. ICON plc. Recent Developments
Table 104. Pharmaceutical Product Development, LLC Corporation Information
Table 105. Pharmaceutical Product Development, LLC Description and Major Businesses
Table 106. Pharmaceutical Product Development, LLC Product Features and Attributes
Table 107. Pharmaceutical Product Development, LLC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Pharmaceutical Product Development, LLC Recent Developments
Table 109. Cobra Bio Corporation Information
Table 110. Cobra Bio Description and Major Businesses
Table 111. Cobra Bio Product Features and Attributes
Table 112. Cobra Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Cobra Bio Recent Developments
Table 114. Paragon Bioservices, Inc. Corporation Information
Table 115. Paragon Bioservices, Inc. Description and Major Businesses
Table 116. Paragon Bioservices, Inc. Product Features and Attributes
Table 117. Paragon Bioservices, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Paragon Bioservices, Inc. Recent Developments
Table 119. Emergent BioSolutions Inc. Corporation Information
Table 120. Emergent BioSolutions Inc. Description and Major Businesses
Table 121. Emergent BioSolutions Inc. Product Features and Attributes
Table 122. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Emergent BioSolutions Inc. Recent Developments
Table 124. CSL Limited Corporation Information
Table 125. CSL Limited Description and Major Businesses
Table 126. CSL Limited Product Features and Attributes
Table 127. CSL Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. CSL Limited Recent Developments
Table 129. BioNTech SE Corporation Information
Table 130. BioNTech SE Description and Major Businesses
Table 131. BioNTech SE Product Features and Attributes
Table 132. BioNTech SE Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. BioNTech SE Recent Developments
Table 134. Wuxi Biologics Corporation Information
Table 135. Wuxi Biologics Description and Major Businesses
Table 136. Wuxi Biologics Product Features and Attributes
Table 137. Wuxi Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Wuxi Biologics Recent Developments
Table 139. Samsung Biologics Corporation Information
Table 140. Samsung Biologics Description and Major Businesses
Table 141. Samsung Biologics Product Features and Attributes
Table 142. Samsung Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Samsung Biologics Recent Developments
Table 144. Boehringer Ingelheim Corporation Information
Table 145. Boehringer Ingelheim Description and Major Businesses
Table 146. Boehringer Ingelheim Product Features and Attributes
Table 147. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Boehringer Ingelheim Recent Developments
Table 149. Novavax, Inc. Corporation Information
Table 150. Novavax, Inc. Description and Major Businesses
Table 151. Novavax, Inc. Product Features and Attributes
Table 152. Novavax, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Novavax, Inc. Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Vaccine Contract Manufacturing Product Picture
Figure 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Attenuated Product Picture
Figure 4. Inactivated Product Picture
Figure 5. Subunit-based Product Picture
Figure 6. Toxoid-based Product Picture
Figure 7. DNA-based Product Picture
Figure 8. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Downstream
Figure 10. Upstream
Figure 11. Human Vaccine Contract Manufacturing Report Years Considered
Figure 12. Global Human Vaccine Contract Manufacturing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 14. Global Human Vaccine Contract Manufacturing Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Human Vaccine Contract Manufacturing Revenue Market Share by Region (2020-2031)
Figure 16. Global Human Vaccine Contract Manufacturing Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Attenuated Revenue Market Share by Player in 2024
Figure 19. Inactivated Revenue Market Share by Player in 2024
Figure 20. Subunit-based Revenue Market Share by Player in 2024
Figure 21. Toxoid-based Revenue Market Share by Player in 2024
Figure 22. DNA-based Revenue Market Share by Player in 2024
Figure 23. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2020-2031)
Figure 24. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2020-2031)
Figure 25. North America Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 27. North America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 34. Europe Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 37. France Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 49. India Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Human Vaccine Contract Manufacturing Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 57. Central and South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Human Vaccine Contract Manufacturing Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Human Vaccine Contract Manufacturing Revenue (US$ Million) in 2024
Figure 63. South America Human Vaccine Contract Manufacturing Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Human Vaccine Contract Manufacturing Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Human Vaccine Contract Manufacturing Revenue (2020-2025) & (US$ Million)
Figure 69. Human Vaccine Contract Manufacturing Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232